Thrombolysis or Anticoagulation for Cerebral Venous Thrombosis

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

December 31, 2016

Study Completion Date

October 31, 2017

Conditions
Sinus Thrombosis, Intracranial
Interventions
DRUG

Endovascular thrombolysis

Endovascular thrombolysis consists of local application of alteplase or urokinase within the thrombosed sinuses. Standard endovascular techniques to mechanically remove clot material, such as thrombosuction, are allowed, but not mandatory.

DRUG

Heparin

The patients randomized to standard care will receive (or continue) either intravenous adjusted dose unfractionated heparin (aPTT value kept within 1.5 to 2.5 times the normal value), or any type of body-weight adjusted low molecular weight heparin in therapeutic dose, according to local custom and international guidelines

Trial Locations (15)

Unknown

Centre hospitalier de l'université de Montréal (CHUM), Montreal

XuanWu Hospital, Beijing

Hôpital Lariboisière, Paris

Academic Medical Centre, Amsterdam

University Medical Centre Groningen, Groningen

St. Antonius hospital, Nieuwegein

Erasmus Medical Centre, Rotterdam

Haga hospital, The Hague

Medical Centre Haaglanden, The Hague

Hospital de Braga, Braga

Hospital da Universidade de Coimbra, Coimbra

Hospital Santa Maria, Lisbon

Hospital Sao Jose hospital, Lisbon

Hospital de Santo António, Porto

Inselspital, University Hospital, Bern

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Dutch Heart Foundation

OTHER

lead

Jan Stam, MD, PhD

OTHER